• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What We’re Reading: Accelerated Approval Questions; Trump Position on Abortion Ban; Therapists Raising Fees


There is discrepancy between the FDA’s accelerated approval decisions and clinical benefits in cancer treatments; former President Donald Trump’s video statement avoids a clear stance on national abortion legislation; 40% of therapists say they will increase their fees this year.

Limited Benefits of Cancer Drugs Granted Accelerated Approval

A recent study found that most cancer drugs granted accelerated approval by the FDA do not demonstrate significant clinical benefits within 5 years, according to The Associated Press. Despite the program’s intent to expedite access to promising treatments, only 43% of these drugs showed clinical benefit in confirmatory trials, raising concerns about patient understanding and informed decision-making. With recent updates to the program granting the FDA more authority, efforts are underway to ensure faster withdrawal of drugs that fail to meet their commitments.

Trump Defers Abortion Decision to States

In a video posted to Truth Social, former President Donald Trump avoided endorsing federal abortion legislation, instead advocating for state-based decisions on the issue, according to The Hill. While reiterating his support for overturning Roe v Wade and emphasizing his role in appointing conservative Supreme Court justices, his statement remained evasive regarding his stance on signing a federal abortion ban, drawing criticism from both anti-abortion activists and Democrats.

Four in 10 Therapists Plan to Raise Fees in 2024

A survey conducted by Heard revealed that 40% of therapists intend to increase their fees in 2024, with inflation and economic uncertainties being cited as contributing factors, according to Fierce Healthcare. Although most therapists reported earning less than $100,000 in gross income and profit from their practices in 2023, many still offer sliding scale fees or pro bono sessions to ensure accessibility. Additionally, despite the popularity of cash payments, most therapists still accept some form of insurance, with Aetna being the most common payer.

Related Videos
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Dr Julie Patterson, National Pharmaceutical Council
Leslie Fish, PharmD.
James Robinson, PhD, MPH, University of California, Berkeley
Related Content
© 2024 MJH Life Sciences
All rights reserved.